Welcome to our dedicated page for AINOS news (Ticker: AIMDW), a resource for investors and traders seeking the latest updates and insights on AINOS stock.
Ainos, Inc. (AIMD, AIMDW) generates news around its efforts to digitize smell for artificial intelligence and to build a SmellTech platform that combines hardware, software, and data. Company updates frequently highlight progress with its AI Nose electronic nose system, the Smell ID data format, and the Smell Language Model (SLM), as well as developments in its biotech program centered on the oral interferon candidate VELDONA.
News coverage for Ainos often focuses on industrial and technology partnerships. The company has announced collaborations with semiconductor solution providers, industrial computing and edge AI companies, and automation and robotics firms to integrate AI Nose into manufacturing and industrial environments. These stories describe how AI Nose is being deployed in semiconductor fabrication, smart factories, and robotic systems to provide real-time environmental sensing, predictive analytics, and alerts.
Investors can also find corporate and capital markets updates in Ainos-related news, including information on its Global Industry Classification Standard reclassification into the technology sector, At The Market Offering Agreement activity, and reverse stock split of its common stock. Earnings releases and business updates provide context on commercialization milestones, pilot programs in senior care and robotics, and the expansion of the company’s SmellTech-as-a-Service model.
For those following AIMDW, the warrant listing associated with Ainos common stock, the news stream offers insight into the company’s strategic direction, platform evolution, and partnerships. Regularly reviewing these articles can help readers understand how Ainos is positioning AI Nose and ScentAI within semiconductors, edge AI, healthcare, and robotics, and how these initiatives relate to its broader dual-platform AI and biotech strategy.
Ainos (NASDAQ:AIMD) reported Q2 2025 financial results highlighting significant commercial progress for its AI Nose scent digitization platform. The company secured its first three-year subscription order worth $2.1 million for semiconductor manufacturing applications and generated initial revenue from the senior care sector.
AI Nose demonstrated strong performance metrics, achieving 85% accuracy in eldercare hygiene detection, 80% in semiconductor facilities, and 90% in food/beverage scent classification. The company unveiled a 90-day roadmap targeting approximately 1,400 pilot deployments, with plans to expand to 5,000 units in Phase 1 and potentially 15,000 units in Phase 2.
Ainos established strategic partnerships with key players including ASE Technology, Solomon, and Kenmec to accelerate AI Nose adoption across robotics, semiconductors, and smart manufacturing. The company also completed a 1-for-5 reverse stock split to regain Nasdaq compliance.
Ainos (NASDAQ:AIMD), a company specializing in AI-powered scent detection, has announced its participation in an upcoming fireside chat with Water Tower Research on August 20, 2025, at 11:00 a.m. ET.
During the chat, the company will discuss its AI Nose technology, recent strategic partnerships, and deployment progress. Management will also address market opportunities, upcoming milestones for 2025-2026, and position Ainos as a core technology company. The event will be available for replay on the company's investor relations website.
Ainos (NASDAQ:AIMD) has secured a significant $2.1 million three-year subscription order with ASE Technology Holding Co. for deploying its AI Nose platform in semiconductor manufacturing. The agreement involves installing 1,400 AI Nose units across three major manufacturing sites in Taiwan through their SmellTech-as-a-Service model.
This marks Ainos' first revenue-generating industrial deployment, following its initial success in the senior care sector in Q1 2025. The company is expanding with pilot deployments at seven sites in Japan through robotics partner ugo, Inc., and advancing multi-site rollouts with Kenmec and Solomon in Taiwan.
The global e-Nose market is projected to grow from $29.8 billion in 2025 to $76.5 billion by 2032. Ainos' proprietary smell language model (SLM) aims to digitize scent into machine-readable Smell ID data, positioning AI Nose as a trainable AI platform for complex olfactory signals.
Ainos (NASDAQ:AIMD) has received approval from Taiwan's Food and Drug Administration (TFDA) to initiate a clinical study for its drug candidate VELDONA® in treating primary Sjögren's syndrome (pSS). The open-label study will commence at Taipei Medical University-Shuang Ho Hospital in October 2025, with completion expected in H1 2027.
VELDONA®, a low-dose oral interferon-alpha drug, has previously demonstrated significant efficacy in three large U.S. clinical trials involving 497 patients, with 300 receiving VELDONA® treatment. The drug showed notable improvement in dryness-related symptoms without serious adverse events.
Primary Sjögren's syndrome affects between 400,000 and 3.1 million people globally, with no FDA-approved therapies currently available for this chronic autoimmune disorder.
Ainos (NASDAQ:AIMD) received recognition from Water Tower Research for its AI Nose platform, an advanced smell digitization technology. The platform demonstrates impressive accuracy rates: 90+% in distinguishing everyday scents, 85% in senior care environments, and 80% across 22 industrial scent types in semiconductor settings.
Built on over a decade of innovation, AI Nose combines advanced calibration, high-precision signal processing, and custom sensor arrays. The technology utilizes a smell language model (SLM) that improves with continuous use, creating a data-driven flywheel effect. The company is pursuing strategic partnerships, particularly in Asia, to accelerate commercialization across healthcare, industrial, and robotics markets.
Ainos (NASDAQ:AIMD) has announced a groundbreaking partnership with ugo Inc. to launch the world's first AI Nose-enabled service robots across seven pilot sites in Japan. The robots will be deployed in pharmaceutical manufacturing, facility management, energy operations, power substations, and water treatment plants.
The AI Nose technology has demonstrated impressive accuracy rates: 80% accuracy across 22 industrial scent types in semiconductor facilities, 85% accuracy in senior care pilots, and over 90% accuracy in food and beverage testing. The company plans to deploy approximately 1,400 AI Nose units with ASE and expand to 5,000 units in Phase 1.
This initiative is part of Ainos' 90-day action plan and positions the company for a global SmellTech-as-a-Service rollout in 2026. The global electronic nose market is projected to grow from $29.79 billion in 2025 to $76.45 billion by 2032.
Ainos (NASDAQ:AIMD) has regained Nasdaq compliance and unveiled its 90-day roadmap for scaling its AI Nose platform. The company reported significant achievements, including a 412% year-over-year revenue increase in Q1 2025 and strategic partnerships with major industry players like ASE Technology Holding for deploying up to 15,000 AI Nose units.
The company's proprietary smell language model (SLM) has achieved 90% accuracy in classifying everyday scents, while its senior care program improved to 85% accuracy. Key partnerships with Kenmec and Solomon aim to integrate AI-powered scent intelligence into smart factory systems. The company also completed the first-ever integration of AI Nose with a humanoid robot through ugo Inc.
Ainos's 90-day plan focuses on deploying 1,400 AI Nose units with ASEH, expanding to 5,000 units, and launching SmellTech-as-a-Service (SaaS) as a subscription-based revenue model.
Ainos (NASDAQ:AIMD) received a new Water Tower Research report highlighting the company's commercial advancement in industrial AI through its AI Nose technology. The report spotlights several high-impact partnerships that position Ainos' digital olfaction platform for significant market expansion.
Key partnerships include: ASE Technology Holding, planning to deploy up to 15,000 AI Nose units; Kenmec, manufacturing and deploying AI Nose across infrastructure applications; and Solomon Technology, with a five-year agreement integrating AI Nose into Asia's manufacturing sectors. The company's smell language model (SLM) technology is set for scaled pilot programs in H2 2025, with potential multi-million-dollar recurring revenues through a SmellTech-as-a-Service subscription model starting 2026.
Ainos (NASDAQ:AIMD) has announced a strategic five-year distribution partnership with Solomon Technology Corporation to expand its AI Nose platform across Asia's industrial sectors. The partnership combines Ainos' smell language model (SLM) with Solomon's Visual Language Model (VLM) to create an advanced sensory intelligence platform.
The collaboration targets key manufacturing sectors including semiconductors, petrochemicals, autonomous mobile robots (AMRs), and healthcare. This expansion builds on Ainos' existing partnerships with ASE, Kenmec, and ugo. The global electronic nose market is projected to grow from $29.8B in 2025 to $76.5B by 2032, with Asia controlling over 70% of global semiconductor capacity and 45% of electronics manufacturing services.
Ainos (NASDAQ:AIMD) has completed a 1-for-5 stock consolidation effective June 30, 2025, while announcing significant progress in its AI-powered olfactory intelligence business. The company is targeting the electronic nose market, projected to grow from $29.8 billion in 2025 to $76.5 billion by 2032.
The company has established key partnerships for AI Nose deployment: ASE Technology Holding (planning deployment of 1,400 units in pilot phase, scaling to 5,000 in Phase 1 and 15,000 in Phase 2), Kenmec Mechanical Engineering for smart factory integration, and ugo for robotics applications in Japan. In Q1 2025, Ainos reported a 412% year-over-year revenue growth.
The company's Smell Language Model (SLM) has achieved over 90% accuracy in classifying meat, food, and beverage samples. In the senior care sector, their technology demonstrated 85%+ accuracy in hygiene detection across 2,000+ samples. Additionally, Ainos is advancing clinical trials for VELDONA® in Taiwan for HIV-related oral warts and Sjögren's syndrome.
FAQ
What is the current stock price of AINOS (AIMDW)?
